Icon

THYRO-TABS (nda021116)- (0.025MG,0.025MG,0.025MG,0.025MG,0.05MG,0.05MG,0.05MG,0.05MG,0.075MG,0.075MG,0.075MG,0.075MG,0.088MG,0.088MG,0.088MG,0.088MG,0.1MG,0.1MG,0.1MG,0.1MG,0.112MG,0.112MG,0.112MG,0.112MG,0.125MG,0.125MG,0.125MG,0.125MG,0.137MG,0.137MG,0.137MG,0.137MG,0.15MG,0.15MG,0.15MG,0.15MG,0.175MG,0.175MG,0.175MG,0.175MG,0.2MG,0.2MG,0.2MG,0.2MG,0.3MG,0.3MG,0.3MG,0.3MG)

LEVOTHYROXINE SODIUM ALVOGEN
0.025MG,0.025MG,0.025MG,0.025MG,0.05MG,0.05MG,0.05MG,0.05MG,0.075MG,0.075MG,0.075MG,0.075MG,0.088MG,0.088MG,0.088MG,0.088MG,0.1MG,0.1MG,0.1MG,0.1MG,0.112MG,0.112MG,0.112MG,0.112MG,0.125MG,0.125MG,0.125MG,0.125MG,0.137MG,0.137MG,0.137MG,0.137MG,0.15MG,0.15MG,0.15MG,0.15MG,0.175MG,0.175MG,0.175MG,0.175MG,0.2MG,0.2MG,0.2MG,0.2MG,0.3MG,0.3MG,0.3MG,0.3MG
No Yes
Expired Expired
None None
None No
Levothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
4 0 2
Total Other Developers 2
Drugs with Suitability No
0.025MG ** ** - - -
0.05MG ** ** - - -
0.075MG ** ** - - -
0.088MG ** ** - - -
0.1MG ** ** - - -
0.112MG ** ** - - -
0.125MG ** ** Down - -
0.137MG ** ** - - -
0.15MG ** ** - - -
0.175MG ** ** - - -
0.2MG ** ** - - -
0.3MG ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** ****** *** ****** *************** *** *********** *** * ********** **, ******* *****, *** **** (**) *****, ****** ****** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.